Our new unit at St George's Hospital is open for business

Posted:
8
January 2004

8th January 2004Our new unit at St George's Hospital is open for businessThe opening of our second unit makes Richmond Pharmacology the largest phase I CRO in the UK. Our total capacity across the two sites has increased to 90 beds.The new unit is located in the Knightsbridge Wing of St George’s Hospital, Tooting, London. Situated within refurbished, access-controlled facilities and run by the same dedicated and highly trained team of over 80 staff already working at our Atkinson Morley’s Hospital Unit.We have made a further significant investment in our state of the art equipment with networked 12 lead Marquette ECGs at every bed.St George’s Healthcare Trust is one of the largest and busiest National Health Service Trusts in the country. As well as providing general and acute services, the hospital offers a range of specialist, teaching and research facilities with links to the services of St Georges Hospital Medical School.St George’s Hospital Medical School. The even closer proximity to the Medical School provides further opportunities for joint academic research, specialist studies or patient trials.Richmond Pharmacology’s new unit is one of the only commercial Phase I CROs with facilities located within the same site as both the Teaching Hospital and Medical School.To request a brochure on our new facilities or to arrange a site visit please contact Claire Tucker today.

Latest news

Upcoming Event

The 41st Annual Scientific Meeting of the Japanese Society of Clinical Pharmacology and Therapeutics (JSCPT)

4 – 5 December 2020
The 41st Annual Scientific meeting focuses on international collaboration in the pursuit of drug discovery and drug development.
View event

Contributing to our community in 2020

December 17, 2020
Richmond Pharmacology has a long-standing tradition of supporting local, national, and international charities and 2020 is no exception.
Read more

Richmond Pharmacology supports Cardior Pharmaceuticals with the pioneering trial of an oligonucleotide-based drug in heart failure patients

December 14, 2020
Richmond Pharmacology is delighted to welcome the positive Phase Ib results of Cardior Pharmaceuticals lead compound CDR132L for heart failure.
Read more

Marking a milestone for gene editing

November 10, 2020
We are pleased to share that Richmond Pharmacology, in partnership with Intellia Therapeutics and the Royal Free Hospital, have treated the first patient in a landmark CRISPR/Cas9 clinical trial of NTLA-2001
Read more